Fabio A.B. Schutz

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo de Velasco, Youjin Je, Dominick Bossé et al. · Cancer Immunology Research · 2017 · 476 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

Joaquim Bellmunt, Toni K. Choueiri, Ronan Fougeray et al. · Journal of Clinical Oncology · 2010 · 454 citations

Medicine, Oncology, Chemotherapy +11

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Robert J. Motzer, Bernard Escudier, Saby George et al. · Cancer · 2020 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17

Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes

Fabio A.B. Schutz, Youjin Je, Georges Azzi et al. · Annals of Oncology · 2010 · 141 citations · Full text

Medicine, Oncology, Pharmacotherapy +7